Proteomics

Dataset Information

0

Quantitative proteomic profiling of cerebrospinal fluid to identify candidate biomarkers for Alzheimer’s disease

ABSTRACT: Alzheimer's disease (AD) is the most prevalent form of dementia and the number of AD patients is expected to increase as human life expectancy improves. The deposition of β-amyloid protein (Aβ) in the extracellular matrix and neurofibrillary tangles intracellularly are pathologic hallmarks of AD in the brain. However, there are no reliable circulating biomarkers for accurate diagnosis of AD. In this study, we employed high-resolution mass spectrometry and tandem mass tags (TMT) to identify candidate biomarkers for Alzheimer’s disease. A subset of the identified candidates was validated using multiplexed targeted PRM-LC-MS/MS analysis in an independent cohort.

INSTRUMENT(S): Orbitrap Fusion Lumos, Q Exactive HF, Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cerebrospinal Fluid

DISEASE(S): Alzheimer's Disease

SUBMITTER: Akhilesh Pandey  

LAB HEAD: Akhilesh Pandey

PROVIDER: PXD008098 | Pride | 2019-01-10

REPOSITORIES: Pride

Json Xml

Dataset's files

Source:
Action DRS
CSF_AD_MARS_10_R1.raw Raw
CSF_AD_MARS_10_R2.raw Raw
CSF_AD_MARS_11_R1.raw Raw
CSF_AD_MARS_11_R2.raw Raw
CSF_AD_MARS_12_R1.raw Raw
Items per page:
1 - 5 of 51
altmetric image

Publications

Quantitative Proteomic Profiling of Cerebrospinal Fluid to Identify Candidate Biomarkers for Alzheimer's Disease.

Sathe Gajanan G   Na Chan Hyun CH   Renuse Santosh S   Madugundu Anil K AK   Albert Marilyn M   Moghekar Abhay A   Pandey Akhilesh A   Pandey Akhilesh A  

Proteomics. Clinical applications 20190125 4

<h4>Purpose</h4>The aim of this study is to identify the potential cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease and to evaluate these markers on independent CSF samples using parallel reaction monitoring (PRM) assays.<h4>Experimental design</h4>High-Resolution mass spectrometry and tandem mass tag (TMT) multiplexing technology are employed to identify potential biomarkers for Alzheimer's disease. Some of the identified potential biomarkers are validated using PRM assays.<h4>Resul  ...[more]

Similar Datasets

Proteomics Quantitative proteomic profiling of brain in Alzheimer’s disease
2022-04-01 | PXD010560 | Pride
Proteomics Phosphoproteomic analysis of brain form Alzheimer’s disease
2021-09-08 | PXD010807 | Pride
Proteomics The Periodontal Pathogen Fusobacterium nucleatum Exacerbates Alzheimer’s Pathogenesis via Specific Pathways
2022-08-12 | PXD033147 | Pride
Proteomics Molecular alterations elicited by chronic exposure to cigarette smoke in oral keratinocytes
2018-03-05 | PXD007637 | Pride
Proteomics Ultra Deep Mouse cerebrospinal fluid (CSF) profiling in Alzheimer’s disease
2021-09-09 | PXD018658 | Pride
Proteomics Molecular alterations elicited by chronic exposure to cigarette smoke and chewing tobacco in oral keratinocytes
2019-11-08 | PXD007127 | Pride
Proteomics Discovery of biomarkers for amyotrophic lateral sclerosis from human cerebrospinal fluid using mass spectrometry-based proteomics
2023-05-22 | PXD038846 | Pride
Proteomics AAV-based gene therapy prevents and halts the progression of dilated cardiomyopathy in a new mouse model of inherited phosphoglucomutase 1 deficiency (PGM1-CDG)
2023-08-18 | PXD036271 | Pride
Proteomics Proteome-wide changes in primary skin keratinocytes exposed to diesel particulate extract – a role for antioxidants in skin health
2018-11-06 | PXD006743 | Pride
Proteomics Profilling of aggregated proteome in human control and AD cases
2022-08-12 | PXD031587 | Pride